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Cervical cancer is the third most common gy-necological cancer in the United States and the second most common cancer in women 
worldwide.1 Most cases occur in developing countries. 
As such, the International Federation of Gynecology 
and Obstetrics (FIGO) staging classification prohibits 
the use of CT, magnetic resonance imaging (MRI) and 
PET in an attempt to eliminate the disparities in staging 
around the world. Furthermore, the FIGO staging sys-
tem does not currently incorporate lymph node status 
(pelvic or para-aortic), which is considered one of the 
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BACKGROUND AND OBJECTIVE: In recent years, the role of positron emission tomography (PET) in the stag-
ing and management of gynecological cancers has been increasing. The aim of this study was to systematically 
review the role of PET in radiotherapy planning and brachytherapy treatment optimization in patients with 
cervical cancer.
DESIGN AND SETTING: Systematic literature review. 
METHODS: Systematic review of relevant literature addressing the utilization of PET and/or PET-computed 
tomography (CT) in external-beam radiotherapy planning and brachytherapy treatment optimization. We per-
formed an extensive PubMed database search on 20 April 2011. Nineteen studies, including 759 patients, 
formed the basis of this systematic review. 
RESULTS: PET/ PET-CT is the most sensitive imaging modality for detecting nodal metastases in patients with 
cervical cancer and has been shown to impact external-beam radiotherapy planning by modifying the treatment 
field and customizing the radiation dose. This particularly applies to detection of previously uncovered para-
aortic and inguinal nodal metastases. Furthermore, PET/ PET-CT guided intensity-modulated radiation therapy 
(IMRT) allows delivery of higher doses of radiation to the primary tumor, if brachytherapy is unsuitable, and to 
grossly involved nodal disease while minimizing treatment-related toxicity. PET/ PET-CT based brachytherapy 
optimization allows improved tumor-volume dose distribution and detailed 3D dosimetric evaluation of risk 
organs. Sequential PET/ PET-CT imaging performed during the course of brachytherapy form the basis of “adap-
tive” brachytherapy in cervical cancer. 
CONCLUSIONS: This review demonstrates the effectiveness of pretreatment PET/ PET-CT in cervical cancer 
patients treated by radiotherapy. Further prospective studies are required to define the group of patients who 
would benefit the most from this procedure. 
most important predictors of treatment response and 
overall survival. Secondary to the insensitivity of CT 
and MRI in detecting nodal metastases, surgical staging 
was necessary.2 PET using 2-deoxy-2-fluoro-D-glucose 
(FDG) identifies tumor metabolism and can visualize 
metabolic changes within the primary tumor and nodal 
and distant metastases.3 As a result, numerous studies 
have described the use of PET in the primary staging, 
evaluation of treatment response, detection of relapse 
and surveillance of cervical cancer patients.4 Moreover, 
pretreatment-PET could uncover occult metastases 
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outside pelvic and para-aortic lymph nodes (PALNs).5 
However, only a limited number of studies have ad-
dressed the role of PET in radiotherapy planning. 
Furthermore, until recently, there were no randomized 
clinical trials evaluating the utilization of PET in the ra-
diotherapy planning of cervical cancer patients.6 In like 
manner, the role of PET in brachytherapy treatment 
optimization requires further clarification. The aim of 
this study was to systematically review and investigate 
the current role of PET/ PET-CT in external-beam 
radiotherapy planning and brachytherapy treatment 
optimization in cervical cancer patients. 
METHODS
A comprehensive PubMed search was conducted on 
20 April 2011. The following search terms were used; 
“cervical cancer”, “positron emission tomography”, “ra-
diotherapy”, “external-beam” and “brachytherapy”. No 
restrictions were applied to the date of publication; 
however, this search was limited to papers in English. 
Reports describing the utilization of PET/ PET-CT in 
radiotherapy planning and brachytherapy optimization 
for cervical cancer were considered. Studies assessing 
the role of PET/ PET-CT in the staging or surveillance 
of cervical cancer were excluded if no direct inference 
was made to the impact on radiotherapy planning and/
or brachytherapy optimization. Furthermore, reference 
lists of included studies were hand-searched to identify 
relevant missing publications. Articles were assessed 
and selected for inclusion by all authors. Full-text ar-
ticles of eligible abstracts were reviewed. All types of 
studies were included. Data pertaining to date of publi-
cation, study design, number of patients, effect of PET/ 
PET-CT on staging, radiation field and dose, therapeu-
tic outcomes and associated toxicity were extracted us-
ing a predefined datasheet. 
RESULTS
The preliminary search yielded 70 abstracts. Four non-
English publications were excluded. Out of the remain-
ing 66 studies, 27 were excluded following first screen 
of the title and abstract. Thirty-nine full-text articles 
were retrieved for detailed evaluation of which 22 were 
ineligible (did not address radiotherapy planning). 
Additionally, two papers were identified from the ref-
erence lists of included reports. Overall, 19 studies met 
the inclusion criteria and formed the basis of this sys-
tematic review (Figure 1). Analysis involved 724 cer-
vical cancer patients in studies addressing the role of 
PET/ PET-CT in external-beam radiotherapy plan-
ning (10 articles) and 35 patients in studies address-
ing PET/ PET-CT in brachytherapy optimization (3 
articles). The remaining six articles included relevant 
information relating to the use of PET/ PET-CT in 
radiotherapy planning/brachytherapy optimization 
(reviews and non-analyzable original papers) and were 
incorporated into the discussion section. 
PET/ PET-CT in external-beam radiotherapy
Ten original articles were found. There were five pro-
spective studies including one randomized-controlled 
trial (Table 1). Tsai and colleagues4 reported a pro-
spective, randomized open-label clinical trial to deter-
mine the impact of PET on the detection of extrapel-
vic metastases and radiation field design. Previously-
untreated stage I-IVA cervical cancer patients with 
MRI findings of positive pelvic, but negative PALNs 
were included. Eligible patients were randomized 
to receive either pretreatment PET or not. FDG ac-
cumulation was interpreted based on visual analysis 
and reported using a 5-point grading system. Scores 
≥3 were considered positive. Findings from MRI and 
PET were used to determine the need for extended- 
versus standard-radiation fields in the control and 
study groups, respectively. A total of 129 patients were 
randomized. Both groups were well balanced in base-
Figure 1. Search strategy and study selection.
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Table 1. Details of studies addressing the role of PET/ PET CT in external-beam radiotherapy planning.  
Study Date published/ study design 
Comparative 
study?
Number of 
patients 
undergoing 
PET/ PET-CT 
radiotherapy 
planning
Primary 
PET-CT 
simulation 
PET/ PET-
CT used to 
define GTV
PET/ PET-
CT used to 
define nodal 
involvement
Cutoff SUV
Number of 
patients with 
PET/ PET-CT 
nodal positivity 
Number of 
patients in 
which PET/ PET-
CT upstaged 
tumor
Number of 
patients in 
which PET/ 
PET-CT altered 
radiotherapy 
field 
Tsai et al4
2010/
Prospective 
randomized open-
label 
Yesa 66 No No Yes Visual analysis 48 (73%) 7 (6 PALNs, 1 omental nodule) 7 (11%)
Kidd et al7 2010/Prospective Yesd 135 No Yes Yes 40% threshold volume 67 (49.6%) NA NA
Chao et al8 2008/Prospective No 47 No No Yes Visual analysis 37 (78.7%)
e
8 (17%)  were 
found to harbor 
SCLN and ILN 
metastases 
8 (17%)
7 received 
additional 
radiation to 
SCLN
1 received 
additional  
radiation to ILNf
Bjurberg et al3 2009/Prospective No 32 No No Yes Visual analysis 11 (34.4%)
6 (18.8%) 
Previously 
undetected LNs
None
Yildirim et al9 2008/Prospective No 16 No NA Yes Visual analysis 4 (25%)
2 (12.5%) 
Previously 
undetected 
PALNs
2 (12.5%)
Narayan et al2 2001/Retrospective No 21 No NA Yes Visual analysis 14 (66.7%)8
4 (19%) 
Previously 
undetected 
PALNsi
4 (19%) 
received EFRT 
10
Esthappan et al10 2008/ Retrospective No 10 No
k Yes Yes 40% threshold volume NA NA NA
Vandecasteele 
et al11
2009/
Retrospective No 6 Yes Yes
l Yes NA 4 (66.7%) NA NA
Mutic et al12 2003/Retrospective No 4 No No Yes
m NA NA NA None
Igdem et alm 2008Retrospective 
(case report)n
No 1 Yes Yes Yes NA NA Yeso NA
SUV: Standardized Uptake Value, NA: not available/ not reported, OS: overall survival, PFS: progression-free survival. a129 patients randomly assigned to pretreatment PET/ CT (66 patients) versus control group (63 patients). All patients had positive pelvic LNs 
but negative PALNs on MRI bAuthors stated that a lower boost dose was delivered to patients with PET-uninvolved pelvic LN  cThere were no differences in the 4-year rates of overall survival (79% vs. 85% P=.65), disease-free survival (75 % vs. 77% P=.64), 
and distant metastasis-free survival (82% vs. 78% P=.83) between patients who underwent PET compared with those who did not dPET/ CT-guided IMRT (135 patients) versus conventional radiotherapy (317 patients)  eAll 47 patients exhibited evidence of 
involvement of the PA, inguinal and/or supraclavicular lymph nodes on CT/ MRI  fThe intent of treatment was changed to palliation in an additional 3 patients gNone of the 7 patients who achieved complete response on PET imaging (after a mean dose of 23 Gy) 
relapsed  h2 patients demonstrated negative pelvic LNs on PET but were found to harbor involved LNs after surgical sampling iAfter surgical sampling; 2 patients had confirmation of PALN involvement, one PET positive PALN was false-positive and one patient 
did not undergo surgical staging  j2 patients with PET positive pelvic disease would not have received EFRT since they demonstrated PET-negative small volume PALN involvement on surgical sampling kCT simulation and PET images co-registered manually 
using bony anatomy  lMRI and PET/ CT were used conjunctively to define GTV mAll 4 patients had involved PALNs by PET nAvailable only in abstract form  oOn PET/CT simulation for locally advanced cervical cancer, the patient was found to harbor enlarged 
axillary lymphadenopathy  ith moderate FDG uptake. Subsequent biopsy was consistent with small lymphocytic lymphoma (SLL) 
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Table 1. (cont.) Details of studies addressing the role of PET/ PET CT in external-beam radiotherapy planning.  
Study Number of patients in which PET/ PET-CT altered radiotherapy dose Method of radiotherapy delivery Results Toxicity data 
Tsai et al4 Not clearb Conventional radiotherapy (four field box technique) 
At a median follow-up of 53 months; 
4 out of the 7 patients with modified 
radiotherapy field remained disease 
freec
NA
Kidd et al7 None IMRT 28.% recurrence in IMRT group versus 43.8% in conventional group (p=0.036)
6% GIII or higher GU and GI toxicity  in 
IMRT group versus 17% in non-IMRT 
group (p=0.0351)
Chao et al8 None Conventional
2-year OS rate and PFS rate of the 
whole series was 56.9% and 45.0%.
6 of the 8 patients who received 
additional radiation to the SCLN and ILN 
were alive at the time of publication 
NA
Bjurberg et al3 6 (18.8%) Increase in boost volume Conventional radiotherapy At a median follow-up of 28 months; relapse was detected in 11 patientsg NA
Yildirim et al9 None NA NA NA
Narayan et al2 14 (66.7%) received pelvic LN  boost NA NA NA
Esthappan et al10 10 (60 Gy delivered to PALNs) IMRT NA NA
Vandecasteele 
et al11 None IMRT (arc) NA NA
Mutic et al12
4 (100%)
Dose escalated form 45 Gy to PALNs to 
59.4 Gy
PALNs treated by IMRT.
Pelvis treated by conventional 
radiotherapy 
NA
No toxicity data available. 
33% of the kidneys received more than 
30 Gy
50% of the small intestines received 
more than 22 Gy
Igdem et al13 NA NA NA NA
SUV: Standardized Uptake Value, NA: not available/ not reported, OS: overall survival, PFS: progression-free survival. a129 patients randomly assigned to pretreatment PET/ CT (66 patients) versus control group (63 patients). All patients had positive pelvic LNs 
but negative PALNs on MRI bAuthors stated that a lower boost dose was delivered to patients with PET-uninvolved pelvic LN  cThere were no differences in the 4-year rates of overall survival (79% vs. 85% P=.65), disease-free survival (75 % vs. 77% P=.64), 
and distant metastasis-free survival (82% vs. 78% P=.83) between patients who underwent PET compared with those who did not dPET/ CT-guided IMRT (135 patients) versus conventional radiotherapy (317 patients)  eAll 47 patients exhibited evidence of 
involvement of the PA, inguinal and/or supraclavicular lymph nodes on CT/ MRI  fThe intent of treatment was changed to palliation in an additional 3 patients gNone of the 7 patients who achieved complete response on PET imaging (after a mean dose of 23 Gy) 
relapsed  h2 patients demonstrated negative pelvic LNs on PET but were found to harbor involved LNs after surgical sampling iAfter surgical sampling; 2 patients had confirmation of PALN involvement, one PET positive PALN was false-positive and one patient 
did not undergo surgical staging  j2 patients with PET positive pelvic disease would not have received EFRT since they demonstrated PET-negative small volume PALN involvement on surgical sampling kCT simulation and PET images co-registered manually 
using bony anatomy  lMRI and PET/ CT were used conjunctively to define GTV mAll 4 patients had involved PALNs by PET nAvailable only in abstract form  oOn PET/CT simulation for locally advanced cervical cancer, the patient was found to harbor enlarged 
axillary lymphadenopathy  ith moderate FDG uptake. Subsequent biopsy was consistent with small lymphocytic lymphoma (SLL) 
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line clinical characteristics. Although FDG-avid uptake 
was detected in all primary cervical tumors, only 48 of 
66 (73%) patients demonstrated pelvic lymph node in-
volvement by PET. In 7 (11%) patients, results of pre-
treatment PET lead to modification of radiation fields 
(in 6 patients; the radiation field was extended to cover 
the para-aortic region and in 1 patient the radiation field 
was broadened to cover a previously undetected omen-
tal tumor deposit). Four of these patients remained 
disease-free at the time of follow-up. However, at a me-
dian follow-up of 53 months, there was no difference 
in the 4-year rates of overall survival, disease-free sur-
vival and distant metastases-free survival between both 
trial groups. Kidd et al7 reported a prospective, well-
balanced cohort of 452 patients with newly diagnosed 
cervical cancer. One hundred and thirty five patients 
-treated by PET-CT-guided intensity-modulated ra-
diation therapy (IMRT) were compared to 317 pa-
tients who received conventional-pelvic irradiation. All 
IMRT patients underwent PET-CT imaging, which 
was registered with CT simulation by point and ana-
tomical matching. Using 40% as the threshold volume, 
FDG-avid cervical gross tumor volume (GTV) was de-
lineated. Furthermore, PET-CT was used to define the 
upper borders of the para-aortic fields. Most patients 
in both treatment groups had follow-up with PET-CT 
3 months after the completion of therapy. This initial 
response appeared to correlate significantly with overall 
risk of recurrence (P<.0001) and cause-specific survival 
(P<.0001). However, there was no significant differ-
ence in initial response between IMRT and non-IMRT 
groups. After a mean follow-up 52 months, the IMRT 
group demonstrated improved overall and cause-specif-
ic survival (P<.0001). Furthermore, grade 3 or greater 
bowel and bladder toxicity was significantly lower in 
patients treated by IMRT (P=.0351). 
Chao and colleagues8 assessed the impact of PET/ 
PET-CT on the subsequent management of cervical 
cancer patients with suspected nodal metastases on 
CT and MR images. Forty-seven patients were enrolled 
between 2001 and 2007 of whom; 31 had suspected 
isolated PALN involvement, 8 had suspected PALN 
with other distant nodal involvement, 6 had suspected 
inguinal lymph node (ILN) involvement and 2 patients 
had suspected supraclavicular lymph node (SCLN) 
involvement. Integrated PET-CT was performed in 
all patients after May 2006. Images were interpreted 
visually using a 5-point scoring scale. Patients with in-
volved pelvic LNs received 45 Gray (Gy). In cases of 
PALN involvement, the radiotherapy field was extend-
ed to the T12-L1 intervertebral space. Involved ILNs 
were covered by a large radiotherapy portal and were 
boosted using an electron beam to a total dose of 60-
65 Gy delivered via conventional fractionation. Involved 
SCLNs were treated synchronously with pelvic radio-
therapy via parallel-opposed radiation fields to a total 
dose of 30-60 Gy (conventional fractionation). PET/ 
PET-CT had a positive clinical impact in 21 (44.7%) 
of the 47 study participants. This included 8 patients 
in whom the treatment field was modified (7 patients 
with SCLN and 1 patient with ILN metastases), and 
6 patients were down-staged (4 had ILN involvement 
by MRI and negative PET/ PET-CT findings; subse-
quent biopsies were negative) and in 2 patients, PET/ 
PET-CT showed local disease only in variance to previ-
ous imaging studies. These 2 patients underwent radi-
cal hysterectomy and final pathology confirmed local 
disease. Four patients had involved PALNs on imaging 
studies and were treated by extended field radiothera-
py subsequent to PET endorsement and in 3 patients 
treatment intention was changed to palliation after 
PET discovery of widespread metastases. At a median 
follow-up period of 47 months, the 2-year overall sur-
vival for the whole cohort, patients with histological-
ly-proven PALN and SCLN metastases was 56.9%, 
50.6% and 24.7% respectively. Two of the five patients 
with histologically-proven ILN metastases were alive 
with no evidence of disease at the time of follow-up. 
Bjurberg et al3 evaluated the predictive value of 
PET performed early during the course of irradiation. 
In this study, all 32 included patients underwent base-
line PET scanning prior to delivery of radiotherapy. 
Six patients with no previous known nodal metastases 
demonstrated PET-positive lymph nodes. In these pa-
tients, the radiotherapy plan was adjusted via increas-
ing the boost volume. Yildirim et al9 enrolled 16 stage 
IIB-IVA cervical cancer patients with no evidence of 
PALN involvement by conventional CT in an attempt 
to assess whether PET-CT would change the thera-
peutic management plan in these patients. After PET-
CT scanning, all patients underwent pelvic and para-
aortic lymphadenectomy. Pathologically, 4 patients 
harbored PALN metastases. PET-CT disclosed 2 
true-positive, 2 false-positive and 2 false-negative cas-
es of PALN metastases. Extended field radiotherapy 
was offered to the patients with confirmed PALN in-
volvement. 
Narayan and colleagues2 investigated whether PET 
and/or MRI scanning can obviate the need for surgi-
cal staging in patients with locally advanced cervical 
cancer who would normally receive irradiation. This 
study showed that 14 of 27 patients would have been 
treated with pelvic boost if PET was utilized as op-
posed to only 6 if MRI was solely used. Furthermore, 
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pretreatment PET scanning would have necessitated 4 
patients to receive additional extended-field radiation 
therapy (EFRT). Esthappan et al10 reported the ra-
diation planning details of 10 cervical cancer patients 
with involved PALN who were treated by IMRT. 
PET-CT was performed prior to CT simulation. 
Image sets were manually registered using bony anat-
omy. Gross tumor, para-aortic and pelvic nodal disease 
were contoured in FDG-avid regions exhibiting more 
than 40% peak activity. Sixty Gy were prescribed to 
metabolic nodal volume while nodal planning target 
volume (PTV) received 50 Gy. Concerning the radio-
therapy dose delivered to the kidneys, vertebral bod-
ies and intestines, approximately 50% of the kidney 
received at least 16 Gy, 50% of each vertebral body 
received at least 44 Gy and less than 15% of the vol-
ume of the bowels received at least 45 Gy. These DVH 
parameters could form the basis for achievable optimi-
zation targets in patients treated with dose-escalated 
EFRT. Disappointingly, data relating to toxicity and 
outcome are missing from this retrospective analysis. 
Vandecasteele and colleagues11 reported 6 patients 
with locally advanced cervical cancer treated by in-
tensity modulated arc therapy delivered via simul-
taneous integrated boost technique. Four patients 
demonstrated nodal involvement in the iliac lymph 
nodes. Simulation via an integrated PET-CT in the 
treatment position was undertaken to delineate both 
cervical GTV (in conjunction with MRI) and in-
volved lymph nodes. A median dose of 58 and 47 Gy 
were delivered to the nodal GTV and PTV, respec-
tively. Toxicity data and therapeutic outcomes were 
not reported. Mutic et al12 assessed the technical and 
dosimetric feasibility of dose escalation in 4 cervical 
cancer patients with PALN involvement. CT simula-
tion and PET images were registered using anatomi-
cal references. A 2 field, mono-isocentric radiotherapy 
plan was proposed. The whole pelvis up to the L4-L5 
interspace level was treated via conventional parallel-
opposed AP-PA fields delivering a total dose of 50.4 
Gy. At the same time, the PALNs were treated using 
static window-IMRT allowing PET-positive nodal 
GTV and CTV to receive 59.4 and 50.4 Gy, respec-
tively. The lower border of the IMRT field abutted 
the upper border of the conventional pelvic field. The 
dose delivered to the kidneys and small intestines 
were slightly above tolerance doses. However, toxicity 
data was not reported. Iğdem et al13 reported a case in 
which PET-CT performed for radiotherapy planning 
in a locally-advanced cervical cancer patient lead to the 
discovery of axillary lymphadenopathy with moderate 
FDG-avid uptake. Excisional biopsy revealed small 
lymphocytic lymphoma. The patient was treated ac-
cordingly. 
PET/ PET-CT in brachytherapy optimization 
Lin and colleagues14 retrospectively compared the dosi-
metric distribution achieved via conventional or PET-
defined tumor volume in patients with cervical cancer 
(Table 2). All patients had previously undergone PET/ 
PET-CT for nodal staging. Furthermore, PET imag-
ing was conducted in conjunction with the first, middle 
and final high-dose rate (HDR) or both low-dose rate 
(LDR) brachytherapy sessions. Brachytherapy was de-
livered during the course of external-beam irradiation 
via Fletcher-Suit tandem and ovoid applicators. The 
GTV was defined as any area of FDG-avid uptake on 
PET scans identified by 40% peak tumor intensity. No 
additional margins were added. A conventional and a 
3D brachytherapy treatment plan were constructed in 
parallel in each patient. Only HDR plans designed to 
deliver 6.5 Gy to point A were evaluated. The planning 
goal was to cover 80% of the GTV with the 100% iso-
dose line while limiting the dose to 2 cm3 of the blad-
der and 2 cm3 of the rectum to 7.5 and 5 Gy respec-
tively. Eleven patients were evaluated (31 intracavitary 
brachytherapy plans). Three patients demonstrated 
no FDG-avid uptake in the mid or last implants and 
were subsequently excluded from analysis. The re-
sults showed that 73% of the tumor volume was cov-
ered by the 100% isodose line in PET-optimized first 
implant plans as opposed to 68% in the conventional 
plans (P=.21). Similarly, the percent target coverage in 
PET-optimized and conventional plans for the mid/
final implant was 83% and 70% (P=.02), respectively. 
Point A dose was shown to be significantly higher in 
PET-optimized plans in both first (P=.02) and mid/
last implants (P=.008). However, doses to 2 cm3 of the 
bladder (6.2 and 6.8 Gy, P=0.70) and 2 cm3 of the rec-
tum (3.7 and 3.6 Gy, P=.87) were not significantly dif-
ferent among PET-optimized and conventional plans, 
respectively. The authors concluded that PET-based 
optimization successfully allowed improved target dose 
distribution without significantly increasing the radio-
therapy dose to the bladder and rectum. 
The authors had previously conducted a prospective 
study at the same institution aiming to evaluate the uti-
lization of sequential PET imaging for brachytherapy 
planning in patients with cervical cancer.15 Twenty four 
patients were enrolled. All patients were treated with 
a curative intent via external-beam irradiation and in-
tracavitary brachytherapy (LDR and HDR). Although 
PET imaging was used to evaluate volumetric and dosi-
metric considerations of treatment plans, actual brachy-
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Table 2. (cont.) Details of studies addressing PET/ PET-CT based brachytherapy optimization.
Study
Point A dose  by PET-
based, conventional 
planning
Mean ICRU rectal 
reference  dose  by 
PET-based, conventional 
planning
Mean ICRU bladder 
reference  dose by 
PET-based, conventional 
planning
Results Toxicity data 
Lin et al14
First implant: higher in 
PET-based planning 
(P=.02)
Mid and last implant: 
higher in PET-based 
planning (P=0.008)d
2.7, 3.6 Gy 5.1, 4.7 Gy
No significant difference 
in the tumor volume 
coverage during first 
implant. Significant 
difference in tumor 
coverage in mid/last 
implant in favor of PET-
based optimization  
NA
Lin et al15 Not statistically significant 
Not statistically 
significante
Not statistically 
significante
Nine of the eleven 
patients with sequential 
imaging were shown 
to exhibit a decrease in 
tumor size throughout 
treatments
2 patients developed 
late grade IV toxicity 
(pelvic abscess, 
rectosigmoid stricture) 
No late G IV GU toxicity  
 
aTreatment was delivered via conventional 2-D treatment planning. PET-based optimization planning was conducted for comparative purposes. b3 patients had no tumor FDG uptake on the mid or last implant. As 
such these insertions were not assessed. However; data from first implant was included in analysis cFor ease of comparison; PET-based plans were performed for HDR delivery dExact doses not mentioned. Only 
p-value available  e3-D DVH analysis showed that maximal bladder and rectal points and doses to 2 cm3 and 5 cm3 of bladder were significantly greater than ICRU reported bladder and rectal points obtained 
from conventional 2D planning.
Table 2. Details of studies addressing PET/ PET-CT based brachytherapy optimization.
Study Date published/ nature of study
Comparative 
study?
Number of patients 
undergoing PET/ CT 
brachytherapy planning/ 
Number of treatments 
Primary 
PET/ CT 
simulation 
Cutoff SUV Dose rate 
Mean dose to 95% 
of the GTV by PET-
based, conventional 
planning
Lin et al14
2007/
Secondary 
retrospective 
analysis
Yesa 11/31 ICBTb Yes
40% of 
peak 
intensity 
HDR (6.5 Gy x6) 
and LDR (median 
cummulitive dose; 
84.1 Gy)c
First implant: 4.25, 
4.2 Gy
Mid and final 
implants: 4.6, 5.4 Gy
Lin et al15
2005/
Prospective Yes
a 24 Yes
40% of 
peak 
intensity
13 patients were 
treated with HDR 
(median exposure of 
4,800 mgRaEq-h x6) 
and 11 patients 
underwent LDR 
(8,000 mgRaEq-h over 
two insertions)
NA
aTreatment was delivered via conventional 2-D treatment planning. PET-based optimization planning was conducted for comparative purposes. b3 patients had no tumor FDG uptake on the mid or last implant. As 
such these insertions were not assessed. However; data from first implant was included in analysis cFor ease of comparison; PET-based plans were performed for HDR delivery dExact doses not mentioned. Only 
p-value available  e3-D DVH analysis showed that maximal bladder and rectal points and doses to 2 cm3 and 5 cm3 of bladder were significantly greater than ICRU reported bladder and rectal points obtained 
from conventional 2D planning.
therapy treatments were delivered via 2D orthogonal 
planning. Twenty-three patients received concurrent 
cisplatin. GTV was defined as previously stated. Dose 
to point A and rectal and bladder points were obtained 
for PET-optimized and conventional plans. Eleven pa-
tients underwent PET imaging at the first, mid and last 
implant in the case of HDR delivery and both brachy-
therapy implants in the case of LDR delivery. For pa-
tients who underwent sequential PET imaging, this 
study demonstrated a gradually decreasing tumor size 
throughout the brachytherapy procedure. Nine of the 
eleven patients with sequential imaging were shown 
to exhibit a decrease in tumor size throughout treat-
ment. The mean GTV at the time of the first, mid and 
last brachytherapy implant was 37 cm3, 17 cm3 and 10 
cm3, respectively. This translated into a progressively in-
creasing percentage of the tumor volume covered by the 
100% isodose line from 68% for the initial, 76% for the 
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mid and 79% for the last treatment implant. The calcu-
lated dose to 2 cm3, 5 cm3 and the maximum dose to the 
bladder and rectum obtained by PET-based optimiza-
tion were significantly greater than the International 
Commission on Radiation Units and Measurements 
38 (ICRU-38) bladder and rectal points obtained 
through conventional planning. The authors concluded 
that this study could open the door towards delivering 
patient-optimized “adaptive” brachytherapy without 
compromising therapeutic outcomes.
DISCUSSION 
This study represents the first detailed systematic 
review addressing the role of PET/ PET-CT in ra-
diotherapy planning for patients with cervical cancer. 
Unfortunately, most of the included studies were small 
single-center reports. There was only one prospective 
open-label randomized trial in which 129 patients 
were randomly assigned to pretreatment PET-CT ver-
sus a control group.4 
Compared to CT and MRI, PET-CT has been 
shown to be more sensitive in detecting lymph node 
metastases in patients with cervical cancer.9 In 6 of the 
10 original studies addressing the role of PET/ PET-
CT in external-beam radiotherapy planning, pretreat-
ment PET/ PET-CT resulted in upstaging a propor-
tion of patients.2-4,8,9,13 This lead to extension of the ra-
diation portal to cover metabolically involved para-aor-
tic, inguinal or even supraclavicular lymph nodes with 
encouraging survival data. In the study by Tsai et al,4 
4 of 7 patients who received extended-field irradiation 
for PET-detected extrapelvic metastases were alive and 
disease-free at 3 years. In other patients, pretreatment 
PET/ PET-CT showed distant metastatic disease. In 
these patients, the intent of treatment was changed to 
palliation. 
The survival of cervical cancer patients with nodal 
metastases is poor.16,17 As such, involvement of the pel-
vic and/or para-aortic lymph nodes dictates delivery of 
higher doses of radiotherapy to regions of nodal posi-
tivity in the pelvis and/or abdomen.5 Four studies de-
scribed the use of PET/ PET-CT in the identification 
of gross nodal involvement and guidance of accurate 
delivery of dose-escalated irradiation.2,3,10,12 Mutic et 
al12 demonstrated the feasibility of delivering 59.4 Gy 
to PET-involved PALNs via static window IMRT. In 
their proposed technique, a mono-isocentric radiation 
portal would allow the pelvis to be treated with a paral-
lel-opposed conventional method to a dose of 50.4 Gy. 
Esthappan et al10 narrated their experience with the in-
tensity-modulated delivery of 60 Gy to positive PALN 
in patients with locally-advanced cervical cancer. 
The improved therapeutic outcome of concurrent 
chemoradiation for cervical cancer came amidst the 
burden of increased hematological, gastrointestinal 
and genitourinary side effects.7 Due to the undeniable 
improved therapeutic effect in pelvic and para-aortic 
tumors, implementation of PET/ PET-CT-guided 
IMRT is set to decrease treatment-related toxicity.7,11 
Kidd et al7 demonstrated a significantly lower inci-
dence of grade 3 or higher gastrointestinal and geni-
tourinary toxicity in patients treated by PET-guided 
IMRT versus conventional irradiation. In like manner, 
other investigators have shown that lower boost dos-
es might be appropriate for patients with uninvolved 
pelvic lymph nodes by PET-CT.4 This might lead to a 
decrease in treatment-related toxicity without signifi-
cantly compromising outcome. Furthermore, IMRT 
has been proposed as a replacement to brachytherapy 
in patients where brachytherapy is unsuitable or not 
possible. However, target definition is a problem sec-
ondary to the insensitivity of CT in delineating the pri-
mary tumor. In these cases, the utilization of PET-CT 
to guide IMRT planning is applicable. 
The two studies evaluating the role of PET in 
brachytherapy optimization originated from the same 
center.14,15 In this institution, brachytherapy was deliv-
ered using traditional 2D orthogonal planning. PET-
based optimization was conducted for the sole purpose 
of comparison. Nonetheless, several pertinent points 
are: First, PET-based optimization has the potential of 
achieving improved tumor coverage over conventional 
techniques. This should come without significantly in-
creasing the radiotherapy dose delivered to the blad-
der and rectum. Second, sequential PET imaging prior 
to each brachytherapy implant sets the ground for 
the adoption of an “adaptive” brachytherapy regimen. 
However, further detailed studies are required to fully 
assess the safety of “adaptive” brachytherapy and its 
impact on local recurrence and overall survival. It has 
been previously stated that the ICRU bladder point 
dose significantly underestimates the dose to 2 cm3 of 
the bladder.14,18,19 This might be the result of Foley bal-
loon mal-position.18 As such, PET-CT based brachy-
therapy planning is additionally advantaged since it 
enables more accurate estimation of the radiotherapy 
dose delivered to the bladder, and to a lesser extent, the 
rectum since there is a higher degree of concordance 
between the ICRU rectal dose and the dose to 2 cm3 of 
the rectum.14,18,19 
There is increasing use of PET-CT for nodal-staging 
in locally-advanced cervical cancer. Utilization of this 
baseline image for radiotherapy planning is a reason-
able alternative. However, performing a primary PET-
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CT simulation is strongly encouraged since it avoids 
the uncertainties associated with manual co-registration 
of the PET/ PET-CT and the CT simulation images. 
PET-CT simulation should be performed with the pa-
tient in the treatment position with the use of fiducial 
markers and immobilization devices.20 This requires 
the presence of a dedicated PET-CT for radiotherapy 
planning. Images should optimally be interpreted by a 
nuclear medicine physician employing a quantitative or 
semi-quantitative discrimination approach. 
PET/ PET-CT is an effective pretreatment imaging 
modality in cervical cancer patients treated by radio-
therapy. However, the routine use of PET/ PET-CT in 
radiotherapy planning is probably unjustified due to the 
lack of clear evidence and the associated financial bur-
den.4 PET/ PET-CT would likely impact radiotherapy 
planning in patients with a high risk of harboring PALN 
metastases including those with enlarged/involved pel-
vic lymph nodes, involvement of the uterine canal, high 
tumor-grade and advanced clinical stage. In the future, 
integration of PET-CT in radiotherapy practice is set 
to evolve into advanced techniques of dose painting uti-
lizing complex IMRT plans guided by FDG-avid meta-
bolic activity. PET-CT-based brachytherapy optimiza-
tion is feasible and could provide 3D metabolic and do-
simetric information about the tumor and risk organs.14 
Furthermore, changes in the tumor size and uptake of 
FDG during the course of external beam irradiation and 
brachytherapy could theoretically allow more “adaptive” 
brachytherapy plans.15 Nonetheless, due to the paucity 
of data, PET-CT-guided brachytherapy should cur-
rently remain within the context of clinical trials.
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